Enigma Genetics Pitch Deck
Published: November 11, 2025
1. Overview
Enigma Genetics™ is the world's first self-sovereign genetic identity and restoration platform. It empowers individuals to own, audit, and optimize their own genomic and epigenetic data over time. Our mission is to put people in full control of their biological information -- from birth through aging -- by providing portable biological IDs, encrypted personal vaults, and consent-driven data exchange.
This is a category-defining approach: unlike today's passive DNA data holders, Enigma positions users as active custodians of their biology. We are pre-seed (no prior raises) and Draper Associates is our first formal outreach.
2. The Problem
Fragmented Data & Centralized Silos
Today, genomic data are locked in proprietary silos (DTC databases, hospital EHRs, research repos) that limit accessibility and hinder research.
No User Consent/Audit
Individuals have little real control over their DNA once it's out of the lab. Most sharing is governed by opaque terms; there is no built-in audit trail or revocation.
Data Exploitation & Privacy Risks
In recent news, a bankrupt 23andMe sold the data of ~15 million customers, illustrating how consumers lost control of their intimate profiles. Genetic information is effectively immutable.
Untracked Epigenetic Drift
A person's epigenome changes with age, environment, stress and disease. These epigenetic drifts can impact health and aging, yet no consumer product tracks them systematically.
3. The Solution
Imagine a living QR code for your genome: that is Enigma's Cypherglyph™, a compact optical token encoding your genetic identity.
GeneVault™
A personal encrypted cloud vault for ALL your molecular data. Access gated by user consent and multi-layer encryption.
Unifacator™
Biometric Consent Gateway -- every data release requires live authentication. Issues signed consent tokens.
SignaChain™
Blockchain Audit Ledger -- all events immutably recorded. Time-stamps and anchors every transaction.
OmniMind™
AI Analytics Engine -- ingests your data to provide actionable insights, tracks drift vectors, predicts health risks.
4. Product/Service Offering
Enigma is delivered as a modular platform with clear user workflows:
Use Case: Emergency Medical ID
You're unconscious; paramedics scan your Cypherglyph. They immediately see your blood type/allergies and unlock more details. Everything is logged.
Use Case: Research & Monetization
A university needs DNA data. You approve a limited query via Unifacator, the AI query runs in zero-knowledge, and you get compensation via smart contract.
Use Case: Personal Health/Wellness
You update your methylation profile yearly. OmniMind notes a worrying drift, alerts you, and suggests interventions.
5. Technology
Our stack is built on novel encoding, crypto, and AI technologies (patent-pending):
- •Non-standard Optical Token: Concentric data rings with custom fiducials to encode base-call nibbles and methylation deltas.
- •Biometric Consent (Unifacator): Multi-factor biometric engine with secure enclaves -- templates stored only on-device.
- •Blockchain Audit (SignaChain): Permissioned blockchain with zero-knowledge proof techniques for tamper-evident audit.
- •Post-Quantum Readiness: Layered AES-256 with lattice-based schemes to resist future quantum attacks.
- •AI/ML Analytics (OmniMind): Cloud-based with federated learning and differential privacy, incorporating epigenetic aging clocks.
6. Revenue Model
Subscription Vaults
Tiered plans for GeneVault storage and token updates with 80-90% margins
SDK/API Licensing
Enterprise licensing for health systems and research networks
Data Royalty Marketplace
80% of research fees distributed to users, Enigma takes a cut
B2B Integrations
White-label solutions and partnerships with clinics and governments
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Users (vault subscribers) | 10,000 | 30,000 | 50,000 |
| Monthly ARPU | $20 | $25 | $30 |
| ARR (vault) | $2.4M | $9.0M | $18.0M |
| API/SDK sales | $0.5M | $1.5M | $3.0M |
| Marketplace revenue | $0.2M | $0.8M | $2.0M |
| Total ARR | $3.1M | $11.3M | $23.0M |
| Gross Margin | ~60% | ~65% | ~70% |
7. Customer Benefits
Enigma puts users back in the driver's seat:
- •Privacy-By-Design: All data is encrypted and stored for you only. No hidden terms.
- •Visual Feedback (Cypherglyph): Users get a clear, intuitive representation of their genome that changes visibly as methylation changes.
- •Emergency Access with Audit: First responders get what they need instantly, yet all access is logged.
- •Optional Monetization: Users can opt into research and get paid for queries on their data under their own terms.
8. Viral/Network Effects
Enigma's platform fosters organic growth through network effects:
- •Research Opt-In Network: Every new user increases data pool diversity, attracting more studies.
- •Biometric Consent Marketplace: As more apps integrate Unifacator, it becomes the de facto standard.
- •Verifiable Humanity & Reputation: Blockchain logging powers reputation systems that encourage trust.
- •Generative Bio-Art: Users create and share personalized genome art, providing viral word-of-mouth growth.
9. Team
Kenneth J. Clark -- Founder & CEO
A visionary engineer and inventor with deep domain expertise. Ken has a strong background in operations and automation from his tenure at Tesla (where he led patented work on robotic manufacturing systems). He is the named inventor on the core Enigma patents and single-handedly built the MVP architecture, designed the key encoding schemes, and conducted the market analysis.
References & Sources
[1] [11] Blockchain-Enabled Privacy-Preserving Ecosystem for DNA Sequence Sharing
[2] [3] [9] [10] [13] A Blockchain-Based Dynamic Consent Architecture (ConsentChain)
[4] [6] [12] EPIC: 23andMe Privacy and Data Security Analysis
[5] Center for Genetics and Society: Consumer Genetic Privacy
[7] Harvard Medical School: Loss of Epigenetic Information Can Drive Aging
[8] IEEE Paper: Privacy-Preserving Genomic Analysis Using Zero-Knowledge Proofs